Evidence map›Paper›PMID 25941590›Full record

ArticleOncoimmunology2014

Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors.

Christel Devaud, Jennifer A Westwood, Michele Wl Teng, Liza B John, Carmen Sm Yong, Connie Pm Duong, Mark J Smyth, Phillip K Darcy, Michael H Kershaw

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. PD-1/PD-L1 blockade in renal cell cancer.Expert review of clinical immunology · 2017
    Review
  6. Functional role of regulatory T cells in B cell lymphoma and related mechanisms.International journal of clinical and experimental pathology · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Christel DevaudCancer Immunology Research Program; Sir Peter MacCallum Department of Oncology; University of Melbourne ; Parkville, Victoria, Australia.
Jennifer A WestwoodCancer Immunology Research Program; Sir Peter MacCallum Department of Oncology; University of Melbourne ; Parkville, Victoria, Australia.
Michele Wl TengCancer Immune Regulation and Immunotherapy Laboratory; QIMR Berghofer Medical Research Institute ; Brisbane, Queensland, Australia.
Liza B JohnCancer Immunology Research Program; Sir Peter MacCallum Department of Oncology; University of Melbourne ; Parkville, Victoria, Australia.
Carmen Sm YongCancer Immunology Research Program; Sir Peter MacCallum Department of Oncology; University of Melbourne ; Parkville, Victoria, Australia.
Connie Pm DuongCancer Immunology Research Program; Sir Peter MacCallum Department of Oncology; University of Melbourne ; Parkville, Victoria, Australia.
Mark J SmythImmunology in Cancer and Infection Laboratory; QIMR Berghofer Medical Research Institute ; Brisbane, Queensland, Australia.
Phillip K DarcyCancer Immunology Research Program; Sir Peter MacCallum Department of Oncology; University of Melbourne ; Parkville, Victoria, Australia ; Department of Immunology; Monash University ; Prahran, Victoria, Australia.
Michael H KershawCancer Immunology Research Program; Sir Peter MacCallum Department of Oncology; University of Melbourne ; Parkville, Victoria, Australia ; Department of Immunology; Monash University ; Prahran, Victoria, Australia.
Peter MacCallum Cancer Centre · AUUniversity of Melbourne · AUAustralian Regenerative Medicine Institute · AUBiology of Infection · FRQIMR Berghofer Medical Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In many cancers, regulatory T cells (Treg) play a crucial role in suppressing the effector immune response thereby permitting tumor development. Indeed, in mouse models, their depletion can promote the regression of tumors of various origins, including renal cell carcinoma when located subcutaneous (SC). In the present study, we aimed to assess the importance of Treg immunosuppression in the physiologic context of metastatic renal carcinoma (Renca) disease. To that purpose we inoculated renal tumors orthotopically, intra-kidney (IK), in mice. Treg depletions were performed using anti-CD4 antibody in wild type mice or diphtheria toxin (DT) in

Indexed as

CD, cluster of differentiationCTLA-4, cytotoxic T lymphocyte antigen 4depletionDEREG, Depletion of Regulatory T cellsDT, diphtheria toxinDTR, diphtheria toxin receptorFCS, fetal calf serumFoxp3, Forkhead box protein P3FR, folate receptorIFN, interferonIK, intra-kidneyIL, interleukinimmunosuppressionIP, intra-peritonealIV, intravenouslykidney tumorsM2, type-2 immunosuppressive macrophagesmAb, monoclonal antibodyPBS, phosphate-buffered salinePD-1, program cell death protein 1PD-L1, PD ligand 1Renca Ch+ L+, Renca Cherry LuciferaseSC, subcutaneousTCR, T cell receptorTh, T helper cellsTreg, regulatory T cellsT regulatory cellstumor microenvironment

Identifiers

PMID25941590
PMCPMC4368122
OpenAlexW2091381303

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.